Barclays
CADX

Barclays’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Barclays’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-9,200
Closed -$83K – 7926
2013
Q4 		$83K Buy
9,200
+7,800
+557% +$56.3K ﹤0.01% 5812
2013
Q3 		$8K Buy
1,400
+200
+17% +$1.27K ﹤0.01% 6879
2013
Q2 		$8K Buy
+1,200
New +$8.36K ﹤0.01% 7241

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Barclays's CADX Position: Q1 2014 in Review

Barclays sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 11,756 shares — an estimated $105K sold.

Barclays first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $241K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Barclays reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Barclays sold 11,756 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $105K.
  • Barclays first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Barclays's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $241K in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Barclays's 13F filing for Q1 2014, filed 15 May 2014.